Tofisopam

Tofisopam

SCHEMBL4585183

CCC1C(C)=NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21.CCC1C(C)=NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 1.00
PDE4A P27815 2/20 1.00
MEN1 O00255 1/20 1.00
CHRM1 P11229 1/20 1.00
PDE4D Q08499 1/20 1.00
PDE3A Q14432 1/20 1.00
CA2 P00918 1/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HSD17B10 Q99714 2/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.36
ATM Q13315 1/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 2/20 0.36
ALOX5 P09917 1/20 0.35
EPHX2 P34913 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Levotofisopam SCHEMBL5431173 1.00 KMT2A (1.00) KMT2APDE4AMEN1CHRM1PDE4D
Dextofisopam SCHEMBL236796 1.00 KMT2A (1.00) KMT2APDE4AMEN1CHRM1PDE4D
Tofisopam SCHEMBL29832594 1.00 KMT2A (1.00) KMT2APDE4AMEN1CHRM1PDE4D
Dextofisopam SCHEMBL8086913 1.00 KMT2A (1.00) KMT2APDE4AMEN1CHRM1PDE4D
Dextofisopam SCHEMBL29376877 1.00 KMT2A (1.00) KMT2APDE4AMEN1CHRM1PDE4D
Tofisopam SCHEMBL43522 1.00 KMT2A (1.00) KMT2APDE4AMEN1CHRM1PDE4D
Tofisopam SCHEMBL8086894 1.00 KMT2A (1.00) KMT2APDE4AMEN1CHRM1PDE4D
SCHEMBL5426026 0.94 PDE4A (0.88) KMT2APDE4AMEN1CHRM1PDE4D
SCHEMBL5424919 0.94 PDE4A (0.88) KMT2APDE4AMEN1CHRM1PDE4D
SCHEMBL5425481 0.94 PDE4A (0.88) KMT2APDE4AMEN1CHRM1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567162-A4 TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES VELA ACQUISITION CORP (US) 2008-04-30 EP disclosed
EP-1575521-A4 PHARMACEUTICAL COMPOSITION OF 1-(3-HYDROXY-4-METHOXYPHENYL)-4-METHYL-5-ETHYL-7,8-DIMETHOXY-5H-2,3-BENZODIAZEPINE AND USES THEROF VELA ACQUISITION CORP (US) 2008-04-30 EP disclosed
EP-1575521-A2 PHARMACEUTICAL COMPOSITION OF 1-(3-HYDROXY-4-METHOXYPHENYL)-4-METHYL-5-ETHYL-7,8-DIMETHOXY-5H-2,3-BENZODIAZEPINE AND USES THEROF Vela Pharmaceuticals Inc. (US) 2005-09-21 EP disclosed
EP-1567162-A2 TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES Vela Pharmaceuticals Inc. (US) 2005-08-31 EP disclosed
WO-2004073638-A2 METHOD OF LOWERING BODY TEMPERATURE WITH (S)-2,3-BENZODIAZEPINES VELA PHARMACEUTICALS, INC. (US) 2004-09-02 WO disclosed
WO-2004069155-A2 PHARMACEUTICAL COMPOSITION OF 1-(3-HYDROXY-4-METHOXYPHENYL)-4-METHYL-5-ETHYL-7,8-DIMETHOXY-5H-2,3-BENZODIAZEPINE AND USES THEROF VELA PHARMACEUTICALS, INC. (US) 2004-08-19 WO disclosed
WO-2004050616-A2 TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES VELA PHARMACEUTICALS, INC. (US) 2004-06-17 WO disclosed